Trial Profile
Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun Optoral and Certican in comparison to standard immunosuppressive therapy in renal transplant patients with creeping creatinine.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2012
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate mofetil; Mycophenolate sodium; Prednisolone
- Indications Transplant rejection
- Focus Therapeutic Use
- 12 Sep 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 16 Jun 2011 New trial record